197 related articles for article (PubMed ID: 19957378)
41. Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
Jones J; Bentas W; Blaheta RA; Makarevic J; Hudak L; Wedel S; Probst M; Jonas D; Juengel E
Int J Mol Med; 2008 Sep; 22(3):293-9. PubMed ID: 18698487
[TBL] [Abstract][Full Text] [Related]
42. Protease-activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells.
Knight V; Tchongue J; Lourensz D; Tipping P; Sievert W
Hepatology; 2012 Mar; 55(3):879-87. PubMed ID: 22095855
[TBL] [Abstract][Full Text] [Related]
43. Valproic acid inhibits angiogenesis in vitro and in vivo.
Michaelis M; Michaelis UR; Fleming I; Suhan T; Cinatl J; Blaheta RA; Hoffmann K; Kotchetkov R; Busse R; Nau H; Cinatl J
Mol Pharmacol; 2004 Mar; 65(3):520-7. PubMed ID: 14978230
[TBL] [Abstract][Full Text] [Related]
44. Valproic acid-mediated myocardial protection of acute hemorrhagic rat via the BCL-2 pathway.
Wang C; Wang Y; Qiao Z; Kuai Q; Wang Y; Wang X; He M; Li W; He Y; Ren S; Yu Q
J Trauma Acute Care Surg; 2016 May; 80(5):812-8. PubMed ID: 26886004
[TBL] [Abstract][Full Text] [Related]
45. Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells.
Zhao XY; Zeng X; Li XM; Wang TL; Wang BE
Clin Exp Pharmacol Physiol; 2009 Oct; 36(10):963-8. PubMed ID: 19413596
[TBL] [Abstract][Full Text] [Related]
46. Murine hepatic stellate cells veto CD8 T cell activation by a CD54-dependent mechanism.
Schildberg FA; Wojtalla A; Siegmund SV; Endl E; Diehl L; Abdullah Z; Kurts C; Knolle PA
Hepatology; 2011 Jul; 54(1):262-72. PubMed ID: 21488077
[TBL] [Abstract][Full Text] [Related]
47. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
48. Valproic acid inhibits prostate cancer cell migration by up-regulating E-cadherin expression.
Zhang L; Wang G; Wang L; Song C; Wang X; Kang J
Pharmazie; 2011 Aug; 66(8):614-8. PubMed ID: 21901986
[TBL] [Abstract][Full Text] [Related]
49. Modulation of Donor-Specific Antibody Production After Organ Transplantation by Valproic Acid: A Histone Deacetylase Inhibitor.
Ye J; Li J; Zhou M; Xia R; Liu R; Yu L
Transplantation; 2016 Nov; 100(11):2342-2351. PubMed ID: 27140514
[TBL] [Abstract][Full Text] [Related]
50. Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin II axis.
Choi J; Park S; Kwon TK; Sohn SI; Park KM; Kim JI
Int J Obes (Lond); 2017 Nov; 41(11):1702-1709. PubMed ID: 28720877
[TBL] [Abstract][Full Text] [Related]
51. Induction of hepatic differentiation of mouse bone marrow stromal stem cells by the histone deacetylase inhibitor VPA.
Chen Y; Pan RL; Zhang XL; Shao JZ; Xiang LX; Dong XJ; Zhang GR
J Cell Mol Med; 2009 Aug; 13(8B):2582-2592. PubMed ID: 18705698
[TBL] [Abstract][Full Text] [Related]
52. Histone deacetylase inhibitor valproic acid promotes the induction of pluripotency in mouse fibroblasts by suppressing reprogramming-induced senescence stress.
Zhai Y; Chen X; Yu D; Li T; Cui J; Wang G; Hu JF; Li W
Exp Cell Res; 2015 Sep; 337(1):61-7. PubMed ID: 26112217
[TBL] [Abstract][Full Text] [Related]
53. Histone deacetylase inhibition by sodium valproate regulates polarization of macrophage subsets.
Wu C; Li A; Leng Y; Li Y; Kang J
DNA Cell Biol; 2012 Apr; 31(4):592-9. PubMed ID: 22054065
[TBL] [Abstract][Full Text] [Related]
54. Valproic acid promotes neural regeneration of olfactory epithelium in adult mice after methimazole-induced damage.
Ogawa T; Takezawa K; Shimizu S; Shimizu T
Am J Rhinol Allergy; 2014; 28(2):e95-9. PubMed ID: 24717941
[TBL] [Abstract][Full Text] [Related]
55. Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples.
Berendsen S; Frijlink E; Kroonen J; Spliet WGM; van Hecke W; Seute T; Snijders TJ; Robe PA
Neurooncol Adv; 2019; 1(1):vdz025. PubMed ID: 32642660
[TBL] [Abstract][Full Text] [Related]
56. Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.
Kortenhorst MS; Isharwal S; van Diest PJ; Chowdhury WH; Marlow C; Carducci MA; Rodriguez R; Veltri RW
Mol Cancer Ther; 2009 Apr; 8(4):802-8. PubMed ID: 19372553
[TBL] [Abstract][Full Text] [Related]
57. Mechanism of growth inhibition of prostate cancer xenografts by valproic acid.
Sidana A; Wang M; Shabbeer S; Chowdhury WH; Netto G; Lupold SE; Carducci M; Rodriguez R
J Biomed Biotechnol; 2012; 2012():180363. PubMed ID: 23093837
[TBL] [Abstract][Full Text] [Related]
58. The use of valproic acid and multiple sclerosis.
Nielsen NM; Svanström H; Stenager E; Magyari M; Koch-Henriksen N; Pasternak B; Hviid A
Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):262-8. PubMed ID: 25111895
[TBL] [Abstract][Full Text] [Related]
59. Cardio-hepatic metabolic derangements and valproic acid.
Mazzoccoli G; Longhitano C; Vinciguerra M
Curr Clin Pharmacol; 2014 May; 9(2):165-70. PubMed ID: 23237609
[TBL] [Abstract][Full Text] [Related]
60. Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line
Zhou Y; Xu Y; Wang H; Niu J; Hou H; Jiang Y
Oncol Lett; 2014 Jan; 7(1):203-208. PubMed ID: 24348849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
